-transparent.png){kind=logo}
Fourteen patients with advanced measurable colorectal cancer were treated with daunorubicin hydrochloride (DNR). The drug was administered at a dose of 15 mg/m2 on day 1 through 3 and 8 through 10. After a 4-day rest period DNR was given in weekly injections of 15 mg/m2. There were no partial or complete responses. This study failed to confirm the previously reported therapeutic activity of this agent in colorectal carcinoma, using an identical dose and schedule. We have initiated a phase 1 study of daunorubicin to identify a maximum tolerated dose using an every 3-week schedule for future phase II trials in solid tumors.
Related Publications
J Harvey, and
E Bonnem, and
K Grady, and
A Goodman, and
P Schein
March 1996,
British journal of cancer,
J Harvey, and
E Bonnem, and
K Grady, and
A Goodman, and
P Schein
May 1983,
Cancer treatment reports,
J Harvey, and
E Bonnem, and
K Grady, and
A Goodman, and
P Schein
December 1990,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J Harvey, and
E Bonnem, and
K Grady, and
A Goodman, and
P Schein
January 1998,
Annals of oncology : official journal of the European Society for Medical Oncology,
J Harvey, and
E Bonnem, and
K Grady, and
A Goodman, and
P Schein
December 1987,
Cancer treatment reports,
J Harvey, and
E Bonnem, and
K Grady, and
A Goodman, and
P Schein
January 1989,
Cancer chemotherapy and pharmacology,
J Harvey, and
E Bonnem, and
K Grady, and
A Goodman, and
P Schein
February 1986,
Cancer treatment reports,
J Harvey, and
E Bonnem, and
K Grady, and
A Goodman, and
P Schein
June 1987,
Cancer treatment reports,
J Harvey, and
E Bonnem, and
K Grady, and
A Goodman, and
P Schein
November 1993,
Investigational new drugs,
J Harvey, and
E Bonnem, and
K Grady, and
A Goodman, and
P Schein
January 2006,
Sarcoma,
